Beyar Rafael
Rambam Medical Center and Faculty of Medicine, Technion, Isreal Institute of Technology, Haifa, Israel.
Ann N Y Acad Sci. 2008 Mar;1123:232-6. doi: 10.1196/annals.1420.026.
Progress in cardiovascular disease understanding and management continues at an exponential pace. Our understanding of the molecular basis of disease is enhanced by newer molecular measurement techniques, sophisticated models of physiological protein functions, understanding of the genetic foundation for diseases, and the incorporation of population genetic tools in our clinical analysis. In this review, I discuss prevention and therapy of coronary stenosis impeding coronary flows, prevention of acute and chronic manifestation of coronary flow impairment, and interfering with myocardial manifestation of acute or chronic deprivation of coronary flow. Mechanical heart failure and arrhythmias are common causes of myocardial dysfunction that originate, in part, from the loss of myocardial tissue and function. Techniques for interfering with cardiac function, in order to address the molecular mechanisms associated with restenosis, range from pharmacologic to mechanical procedures including mechanical dilation and scaffolding of coronary stenosis. The use of stents with and without drug coating is leading the clinical world of revascularization side-by-side with cardiac bypass surgery. Other topics that are discussed here include managing myocardial damage and acute and chronic pump failure. Finally, population genetics of cardiac health and the potential for genetic therapeutic guidance in managing ischemic cardiovascular diseases are discussed.
在心血管疾病的理解和管理方面,进展仍在以指数级速度持续推进。更新的分子测量技术、复杂的生理蛋白质功能模型、对疾病遗传基础的认识以及在临床分析中纳入群体遗传学工具,都加深了我们对疾病分子基础的理解。在这篇综述中,我将讨论阻碍冠状动脉血流的冠状动脉狭窄的预防和治疗、冠状动脉血流受损的急性和慢性表现的预防,以及干预冠状动脉血流急性或慢性剥夺的心肌表现。机械性心力衰竭和心律失常是心肌功能障碍的常见原因,部分源于心肌组织和功能的丧失。为解决与再狭窄相关的分子机制而干预心脏功能的技术,涵盖了从药理学方法到机械手段,包括冠状动脉狭窄的机械扩张和支架置入。有药物涂层和无药物涂层支架的使用,与心脏搭桥手术并驾齐驱,引领着临床血管重建领域。这里讨论的其他主题包括管理心肌损伤以及急性和慢性泵衰竭。最后,还将讨论心脏健康的群体遗传学以及在管理缺血性心血管疾病中进行基因治疗指导的潜力。